Brickell Biotech, Inc. (FRTX) Misses Q3 EPS by 64c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Fresh Tracks Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 10, 2022 4:05 PM ESTPhase 1 study of FRTX-02 progressing well, with the SAD portion complete and MAD portion underway
Remain on track to report SAD and MAD topline results from the Phase 1 study of FRTX-02 by early 2023
Advancing the development of FRTX-10 through early preclinical stage studies
BOULDER, Colo., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the Company or Fresh Tracks) (Nasdaq: FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune,... More
